Actim Partus 1ngeni product card

Please learn more about the new quantitative Actim Partus 1ngeni and download the product card:

Actim Partus 1ngeni product card

The next generation Actim® Partus 1ngeni not only detects or rules out the risk of preterm or imminent delivery, but also provides precise data about the severity of the risk, giving you the confidence in choosing early and crucial treatment strategies.

Automated confidence in Actim testing

Actim Partus 1ngeni quantitatively measures phosphorylated insulin-like growth factor binding protein-1 (phIGFBP-1) concentration in cervical secretions. The higher the concentration, the higher the risk.

Actim Partus 1ngeni test results are quantified and interpreted, displayed and stored automatically by using the Actim® 1ngeni instrument. This digital point-of-care system is logical and intuitive to use, and provides quantitative test results in just 5 minutes.

Clinical performance

Relative risk of preterm delivery categorized according to phIGFBP-1 concentration in Actim Partus 1ngeni test.

phIGFBP-1 concentration (ng/mL) Delivery
≤ 7 days
≤ 14 days
before 30 weeks
before 34 weeks
before 37 weeks
≤ 2
2.1-9.9 5.3* 1.5 0.5 1.4 1.6*
10.0-49.9 5.8* 2.1 5.8* 3.3** 2.4***
50.0-249.9 7.7* 4.2* 11.5** 4.1** 2.4***
≥ 250 13.5** 11.1*** 20.3*** 8.7*** 3.9***

Relative risk compared to phIGFBP-1 ≤ 2 ng/mL z-statistics significance: *p < 0.05, **p < 0.01, ***p < 0.001.

Actim Partus 1ngeni test is performed using the Actim 1ngeni instrument

  • Fast and easy testing with traceable documentation
    Automated testing and digital data storage save time and ensure assay consistency. The results are reported in just 5 minutes.
  • Clear quantification and interpretation of test results
    The phIGFBP-1 concentration is reported as a numerical value with the description of estimated risk for preterm or imminent labor:
    < 10 ng/mL, low risk of preterm delivery
    ≥ 10 ng/mL, elevated risk of preterm delivery
  • Early prediction of preterm or imminent delivery
    Actim Partus 1ngeni test is taken from cervical secretions in women with intact fetal membranes and can be performed from gestational week 22 onwards. Accurate detection of an elevated risk is crucial for choosing the right treatment early.


Sample collection, Actim Partus 1ngeni Sample extraction, Actim Partus 1ngeni Select test, Actim Partus 1ngeni Salect Patient test, Actim Partus 1ngeni
Dip the dipstick, Actim Partus 1ngeni Liquid front, Actim Partus 1ngeni Cartridge, Actim Partus 1ngeni Test results Actim Partus 1ngeni

Start testing today

Actim® rapid tests are used by medical professionals worldwide. To ensure a prompt delivery, Actim® tests are distributed via local companies

See Distributors  Contact Us

Disclaimer: Product availability and/or labeling may vary from country to country and is subject to varying regulatory requirements. Please contact your local representative for availability.